OR WAIT null SECS
Dosage forms are being shaped by numerous factors, with patient-centricity continuing to be an important driver of decisions in development.
Tumour-infiltrating lymphocyte (TIL) therapies offer a new route to target cancer.
European vaccine manufacturing is being boosted with high level investments.
March 26, 2024
In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
March 07, 2024
New plans laid out by AstraZeneca will see £650 million ($828 million) be invested into the UK.
March 03, 2024
Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.
This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.
March 02, 2024
Given the criticality of fill/finish processes, it is clear that automation is the next technological step.
Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.
February 21, 2024
AstraZeneca has completed its acquisition of Icosavax, gaining the IVX-A12 vaccine candidate that targets RSV and hMPV.
GSK is expanding its respiratory biologics portfolio with its acquisition of Aiolos Bio and its novel therapy, AIO-001.
February 03, 2024
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.
January 24, 2024
Takeda has received FDA approval for HYQVIA, a subcutaneous immunoglobulin for the maintenance treatment of chronic inflammatory demyelinating polyneuropathy.